Research progress on erythroid differentiation of human induced pluripotent stem cells

doi:10.3877/cma.j.issn.2095-1221.2022.02.009

Abstract

Abstract:

Red blood cell transfusion is the main treatment for patients with severe anemia and other hematological diseases, which can reduce morbidity and mortality. At present, the source of red blood cells mainly relies on voluntary blood donation, but there are challenges such as shortage of blood resources, blood group compatibility (ABO and Rh antigens) and increased risk of infection. Differentiation of stem cells into mature erythrocytes in vitro is expected to solve the above problems. Human induced pluripotent stem cells (iPSCs) have unlimited proliferation and multi-directional differentiation ability, and can obtain a large number of erythrocytes after directional induction and differentiation in vitro, meeting the clinical demand for erythrocytes. This article will review the technical development and clinical application of erythroid differentiation of human iPSCs.

Key words: Red blood cell transfusion, Induced pluripotent stem cells, Erythroid differentiation, Clinical application

Miaochun Chen, Gaochun Wu, Tao Liu. Research progress on erythroid differentiation of human induced pluripotent stem cells[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(02): 115-120.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2022.02.009

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2022/V12/I02/115

Figures/Tables 2

References 72

1	Balvers K, van Dieren S, Baksaas-Aasen K, et al. Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy[J]. Br J Surg, 2017, 104(3):222-229.
2	Iqbal N, Haider K, Sundaram V, et al. Red blood cell transfusion and outcome in cancer[J]. Transfus Apher Sci, 2017, 56(3):287-290.
3	Shah FT, Sayani F, Trompeter S, et al. Challenges of blood transfusions in β-thalassemia[J]. Blood Rev, 2019, 37:100588. doi:10.1016/j.blre.2019.100588.
4	Sparrow RL. Red blood cell components: time to revisit the sources of variability[J]. Blood Transfus, 2017, 15(2):116-125.
5	Zhang Y, Wang C, Wang L, et al. Large-scale ex vivo generation of human red blood cells from cord blood CD34(+) cells[J]. Stem Cells Transl Med, 2017, 6(8):1698-1709.
6	Lau SX, Leong YY, Ng WH, et al. Human mesenchymal stem cells promote CD34⁺ hematopoietic stem cell proliferation with preserved red blood cell differentiation capacity[J]. Cell Biol Int, 2017, 41(6):697-704.
7	Daud H, Browne S, Al-Majmaie R, et al. Metabolic profiling of hematopoietic stem and progenitor cells during proliferation and differentiation into red blood cells[J]. N Biotechnol, 2016, 33(1):179-186.
8	Xi J, Li Y, Wang R, et al. In vitro large scale production of human mature red blood cells from hematopoietic stem cells by coculturing with human fetal liver stromal cells[J]. Biomed Res Int, 2013, 2013:807863. doi:10.1155/2013/807863.
9	Douay L, Andreu G. Ex vivo production of human red blood cells from hematopoietic stem cells: what is the future in transfusion?[J]. Transfus Med Rev, 2007, 21(2):91-100.
10	Giarratana MC, Kobari L, Lapillonne H, et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells[J]. Nat Biotechnol, 2005, 23(1):69-74.
11	Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J]. Cell, 2006, 126(4):663-676.
12	Hansen M, von Lindern M, van den Akker E, et al. Human-induced pluripotent stem cell-derived blood products: state of the art and future directions[J]. FEBS lett, 2019, 593(23):3288-3303.
13	Sugimoto N, Eto K. Generation and manipulation of human iPSC-derived platelets[J]. Cell Mol Life Sci, 2021, 78(7):3385-3401.
14	Matsubara H, Niwa A, Nakahata T, et al. Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions[J]. Biochem Biophys Res Commun, 2019, 515(1):1-8.
15	Iriguchi S, Yasui Y, Kawai Y, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy[J]. Nat Commun, 2021, 12(1):430. doi:10.1038/s41467-020-20658-3.
16	Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds[J]. Science, 2013, 341(6146):651-654.
17	Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts[J]. Nat Biotechnol, 2008, 26(1):101-106.
18	Xu J, Yu L, Guo J, et al. Generation of pig induced pluripotent stem cells using an extended pluripotent stem cell culture system[J]. Stem Cell Res Ther, 2019, 10(1):193. doi:10.1186/s13287-019-1303-0.
19	De Los Angeles A, Elsworth JD, Redmond DE Jr. ERK-independent African Green monkey pluripotent stem cells in a putative chimera-competent state[J]. Biochem Biophys Res Commun, 2019, 510(1):78-84.
20	Kim S, Lee SK, Kim H, et al. Exosomes secreted from induced pluripotent stem cell-derived mesenchymal stem cells accelerate skin cell proliferation[J]. Int J Mol Sci, 2018, 19(10):3119. doi:10.3390/ijms19103119.
21	Kim Y, Park N, Rim YA, et al. Establishment of a complex skin structure via layered co-culture of keratinocytes and fibroblasts derived from induced pluripotent stem cells[J]. Stem Cell Res Ther, 2018, 9(1):217.doi:10.1186/s13287-018-0958-2.
22	Sheykhhasan M, Wong JKL, Seifalian AM. Human adipose-derived stem cells with great therapeutic potential[J]. Curr Stem Cell Res Ther, 2019, 14(7):532-548.
23	Workman MJ, Mahe MM, Trisno S, et al. Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system[J]. Nature medicine, 2017, 23(1):49-59.
24	Simara P, Tesarova L, Rehakova D, et al. Reprogramming of adult peripheral blood cells into human induced pluripotent stem cells as a safe and accessible source of endothelial cells[J]. Stem Cells Dev, 2018, 27(1):10-22.
25	Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells[J]. Science, 2007, 318(5858):1917-1920.
26	Li Y, Zhao H, Lan F, et al. Generation of human-induced pluripotent stem cells from gut mesentery-derived cells by ectopic expression of OCT4/SOX2/NANOG[J]. Cellular reprogram, 2010, 12(3):237-247.
27	Zhao HX, Li Y, Jin HF, et al. Rapid and efficient reprogramming of human amnion-derived cells into pluripotency by three factors OCT4/SOX2/NANOG[J]. Differentiation, 2010, 80(2-3):123-129.
28	Wada N, Wang B, Lin NH, et al. Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts[J]. J Periodontal Res, 2011, 46(4):438-447.
29	Haro-Mora JJ, Uchida N, Demirci S, et al. Biallelic correction of sickle cell disease-derived induced pluripotent stem cells(iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiation[J]. Stem Cells Transl Med, 2020, 9(5):590-602.
30	Dorn I, Klich K, Arauzo-Bravo MJ, et al. Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin[J]. Haematologica, 2015, 100(1):32-41.
31	Okumura T, Horie Y, Lai CY, et al. Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34(+) cells using the auto-erasable Sendai virus vector[J]. Stem Cell Res Ther, 2019, 10(1):185.
32	Ebrahimi M, Forouzesh M, Raoufi S, et al. Differentiation of human induced pluripotent stem cells into erythroid cells[J]. Stem Cell Res Ther, 2020, 11(1):483. doi:10.1186/s13287-020-01998-9.
33	Dzierzak E, Philipsen S. Erythropoiesis: development and differentiation[J]. Cold Spring Harb Perspect Med, 2013, 3(4):a011601. doi:10.1101/cshperspect.a011601.
34	Trakarnsanga K, Wilson MC, Heesom KJ, et al. Secretory factors from OP9 stromal cells delay differentiation and increase the expansion potential of adult erythroid cells in vitro[J]. Sci Rep, 2018, 8(1):1983.doi:10.1038/s41598-018-20491-1.
35	Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells[J]. Stem cells, 2009, 27(3):559-567.
36	Lapillonne H, Kobari L, Mazurier C, et al. Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine[J]. Haematologica, 2010, 95(10):1651-1659.
37	Hitomi H, Kasahara T, Katagiri N, et al. Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice[J]. Sci Transl Med, 2017, 9(409):eaaj2300. doi:10.1126/scitranslmed.aaj2300.
38	Olivier EN, Marenah L, McCahill A, et al. High-efficiency serum-free feeder-free erythroid differentiation of human pluripotent stem cells using small molecules[J]. Stem Cells Transl Med, 2016, 5(10):1394-1405.
39	Netsrithong R, Suwanpitak S, Boonkaew B, et al. Multilineage differentiation potential of hematoendothelial progenitors derived from human induced pluripotent stem cells[J]. Stem Cell Res Ther, 2020, 11(1):481. doi:10.1186/s13287-020-01997-w.
40	Wilkinson AC, Ryan DJ, Kucinski I, et al. Expanded potential stem cell media as a tool to study human developmental hematopoiesis in vitro[J]. Exp Hematol, 2019, 76:1-12.e15.
41	Ruiz JP, Chen G, Haro Mora JJ, et al. Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system[J]. Stem Cell Res, 2019, 41:101600. doi:10.1016/j.scr.2019.101600.
42	Suzuki D, Flahou C, Yoshikawa N, et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity[J]. Stem cell reports, 2020, 14(1):49-59.
43	Raya A, Rodríguez-Pizà I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells[J]. Nature, 2009, 460(7251):53-59.
44	Wattanapanitch M, Damkham N, Potirat P, et al. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system[J]. Stem Cell Res Ther, 2018, 9(1):46. doi: 10.1186/s13287-018-0779-3.
45	Simpson CF and Kling JM. The mechanism of denucleation in circulating erythroblasts[J]. J Cell Biol, 1967, 35(1):237-245.
46	Krauss SW, Lo AJ, Short SA, et al. Nuclear substructure reorganization during late-stage erythropoiesis is selective and does not involve caspase cleavage of major nuclear substructural proteins[J]. Blood, 2005, 106(6):2200-2205.
47	Uddin S, Ah-Kang J, Ulaszek J, et al. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells[J]. Proc Natl Acad Sci U S A, 2004, 101(1):147-152.
48	Breton-Gorius J, Vuillet-Gaugler MH, Coulombel L, et al. Association between leukemic erythroid progenitors and bone marrow macrophages[J]. Blood cells, 1991, 17(1):127-142; discussion 142-146.
49	Hanspal M, Hanspal JS. The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact[J]. Blood, 1994, 84(10):3494-3504.
50	Hanspal M, Smockova Y, Uong Q. Molecular identification and functional characterization of a novel protein that mediates the attachment of erythroblasts to macrophages[J]. Blood, 1998, 92(8): 2940-2950.
51	Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome[J]. Blood, 2015, 125(15):2405-2417.
52	Kobayashi I, Ubukawa K, Sugawara K, et al. Erythroblast enucleation is a dynein-dependent process[J]. Exp Hematol, 2016, 44(4):247-256.
53	Keerthivasan G, Liu H, Gump JM, et al. A novel role for survivin in erythroblast enucleation[J]. Haematologica, 2012, 97(10):1471-1479.
54	Moras M, Lefevre SD, Ostuni MA. From erythroblasts to mature red blood cells: organelle clearance in mammals[J]. Front Physiol, 2017, 8:1076. doi:10.3389/fphys.2017.01076.
55	Mei Y, Liu Y and Ji P. Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation[J]. Blood rev, 2021, 46:100740. doi: 10.1016/j.blre.2020.100740.
56	Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis[J]. Mol cancer, 2020, 19(1):5. doi: 10.1186/s12943-019-1127-7.
57	Nishizawa M, Chonabayashi K, Nomura M, et al. Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity[J]. Cell stem cell, 2016, 19(3):341-354.
58	Bissels U, Bosio A, Wagner W. MicroRNAs are shaping the hematopoietic landscape[J]. Haematologica, 2012, 97(2):160-167.
59	Bruchova H, Yoon D, Agarwal AM, et al. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis[J]. Exp Hematol, 2007, 35(11):1657-1667.
60	Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis[J]. Proc Natl Acad Sci U S A, 2008, 105(9):3333-3338.
61	Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation[J]. Proc Natl Acad Sci U S A, 2005, 102(50):18081-18086.
62	Sun Z, Wang Y, Han X, et al. MiR-150 inhibits terminal erythroid proliferation and differentiation[J]. Oncotarget, 2015, 6(40):43033-43047.
63	Zhan M, Miller CP, Papayannopoulou T, et al. MicroRNA expression dynamics during murine and human erythroid differentiation[J]. Exp Hematol, 2007, 35(7):1015-1025.
64	Xu P, Palmer LE, Lechauve C, et al. Regulation of gene expression by miR-144/451 during mouse erythropoiesis[J]. Blood, 2019, 133(23):2518-2528.
65	Hu W, Yuan B, Flygare J, et al. Long noncoding RNA-mediated anti-apoptotic activity in murine erythroid terminal differentiation[J]. Genes Dev, 2011, 25(24):2573-2578.
66	Wahlster L, Daley GQ. Progress towards generation of human haematopoietic stem cells[J]. Nature cell biology, 2016, 18(11):1111-1117.
67	Marx-Blümel L, Marx C, Weise F, et al. Biomimetic reconstruction of the hematopoietic stem cell niche for in vitro amplification of human hematopoietic stem cells[J]. PloS one, 2020, 15(6):e0234638. doi: 10.1371/journal.pone.0234638.
68	Zhou D, Chen L, Ding J, et al. A 3D engineered scaffold for hematopoietic progenitor/stem cell co-culture in vitro[J]. Scientific reports, 2020, 10(1):11485. doi:10.1038/s41598-020-68250-5.
69	Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery[J]. Nat Rev Genet, 2019, 20(7):377-388.
70	Shen J, Zhu Y, Lyu C, et al. Sequential cellular niches control the generation of enucleated erythrocytes from human pluripotent stem cells[J]. Haematologica, 2020, 105(2):e48-e51.
71	Harding J, Mirochnitchenko O. Preclinical studies for induced pluripotent stem cell-based therapeutics[J]. J Biol Chem, 2014, 289(8):4585-4593.
72	Bayley R, Ahmed F, Glen K, et al. The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors[J]. J Tissue Eng Regen Med, 2018, 12(1):e368-e378.

来源	导入的转录因子	参考文献
人成纤维细胞	Oct4, Klf4, Sox2, LIN28	[25]
人肠道肠系膜	OCT4, SOX2, NANOG	[26]
人羊膜	OCT4, SOX2, NANOG	[27]
人牙龈成纤维细胞和牙周韧带成纤维细胞	OCT3/4, SOX2, KLF4, c-MYC	[28]
人骨髓基质细胞	OCT3/4, SOX2, KLF4, c-MYC	[29]
人脐带血	单独表达OCT4和SOX2 （CD34-2F-iPSC）或表达OCT4, SOX2, KLF4和c-MYC（CD34-4F-iPSC）	[30]
人外周血	OCT4, SOX2, KLF4和MYC	[31]

来源	导入的转录因子	参考文献
人成纤维细胞	Oct4, Klf4, Sox2, LIN28	[25]
人肠道肠系膜	OCT4, SOX2, NANOG	[26]
人羊膜	OCT4, SOX2, NANOG	[27]
人牙龈成纤维细胞和牙周韧带成纤维细胞	OCT3/4, SOX2, KLF4, c-MYC	[28]
人骨髓基质细胞	OCT3/4, SOX2, KLF4, c-MYC	[29]
人脐带血	单独表达OCT4和SOX2 （CD34-2F-iPSC）或表达OCT4, SOX2, KLF4和c-MYC（CD34-4F-iPSC）	[30]
人外周血	OCT4, SOX2, KLF4和MYC	[31]

[1]	Yang Guang, Wen He, Jiajun Wu, Mingchang Zhao, Yukang Zhang, Fang Wan. Clinical application of deep learning based ultrasound segmentation of thyroid nodules [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(03): 206-211.
[2]	Minwei Zhao, Xiao Geng, Hongling Chu, Siyan Zhan, Wei Huang, Hua Tian, Kunzheng Wang. Expert consensus on clinical application of 3D printed patient-specific instrumentation for total knee arthroplasty(2023) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(03): 308-310.
[3]	Lian Zhou, Hang Zhou, Dongqiang Zhang, Haitao Xu. Clinical application of the modified lingual arch in treating the ectopic eruption of the permanent mandibular first molar [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(02): 94-99.
[4]	Jiuli Yuan, Dan Liu, Linli Li, Jinyu Liu. Basic research and clinical application of hair follicle-derived mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 189-192.
[5]	Liang Qiao, Xiangqun Yang. Adipose derived stem cells for myocardial injury repair: a review [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(04): 230-236.
[6]	Wei Du, Lijuan Cui, Ying Xu, Hua Zhang, Hongwei Du, Jinmei Zhang, Rongzhi Liu, Zhengyu Wang, Wenling Yang, Yu Zhang. Biological characteristics of natural killer cells from cord blood mononuclear cell-derived induced pluripotent stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2021, 11(06): 329-336.
[7]	Ning Mao, Yong Zhu. Pathogenesis and diagnosis of bile acid diarrhea [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 425-428.
[8]	Chongyang She, Hong Lu. Research progress of Janus kinase inhibitor in the treatment of Juvenile idiopathic arthritis associated uveitis [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(02): 104-108.
[9]	Jiaxi Ma, Qianqian Mi, Yiren Zhou, Dan Wang. Advance on the clinical application of adalimumab in ophthalmology [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(06): 377-381.
[10]	Dongsheng Wang, Lida Wu, Yuchun Gu. Application and challenges of cell and gene therapy in retinal degenerative diseases [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(03): 129-133.
[11]	Shaowei Wu. Recent advance in clinical application of vagus nerve stimulation in improving neurological disorders [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(03): 180-184.
[12]	Na Zhao, Liyun Zhang. Discussion on clinical application of Shengxian decoction [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2022, 11(04): 174-176.
[13]	Shuang Chen, Yan Shen. An overview of principle parameters of electroacupuncture [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2022, 11(03): 107-110.
[14]	Shuai Zhang, Xiangdong Jian, Kaicheng Yang, Zhe Zhang, Qing Wang, Meng Ma, Xue Gong. Application of situation-introduced mind mapping method in emergency clinical teaching [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2022, 08(02): 102-106.
[15]	Junyan Huo, Yu Fu. Clinical application of detection methods for patent foramen ovale [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(05): 310-313.

Please choose a citation manager

Content to export